Table 2.
List of proteins and percentage of samples over the limit of detection (LOD) among the indicating FTA elute micro card™ samples (left column) and the Liguid-based cytology samples (right column); 2 of the 28 Liguid-based cytology samples did not pass the quality controls and were excluded. 7 proteins were detected in all 26 Liguid-based cytology samples, compared to 21 proteins that were detected in the 28 FTA samples.
| Protein | FTA elute micro cardTM (% of samples over LOD) | Protein | Liquid cytology samples (% of samples over LOD) |
|---|---|---|---|
| IL-8 | 100% | IL-8 | 100% |
| VEGF-A | 100% | VEGF-A | 100% |
| AM | 100% | IL-1ra | 100% |
| PlGF | 100% | CSTB | 100% |
| EZR | 100% | U-PAR | 100% |
| IL-1ra | 100% | HE4 | 100% |
| CSTB | 100% | PRSS8 | 100% |
| MCP-1 | 100% | MCP-1 | 96% |
| TNF-R1 | 100% | TNF-R1 | 96% |
| PARK7 | 100% | CEA | 96% |
| FADD | 100% | EZR | 92% |
| FAS | 100% | hK11 | 92% |
| EMMPRIN | 100% | Ep-CAM | 92% |
| LITAF | 100% | CXCL5 | 92% |
| CASP-3 | 100% | TF | 88% |
| CDKN1A | 100% | FAS | 88% |
| TGF-alpha | 100% | EMMPRIN | 88% |
| HE4 | 100% | CASP-3 | 88% |
| eIF-4B | 100% | FR-alpha | 88% |
| CA-125 | 100% | GDF-15 | 85% |
| PRSS8 | 100% | MK | 85% |
| GDF-15 | 96% | TGF-alpha | 85% |
| TF | 96% | CXCL13 | 85% |
| CXCL9 | 96% | VIM | 85% |
| PTPN22 | 96% | PlGF | 81% |
| CXCL10 | 96% | IL-6 | 81% |
| CXCL5 | 96% | CXCL10 | 77% |
| MK | 96% | HGF | 77% |
| U-PAR | 96% | AR | 77% |
| LYN | 96% | CXCL9 | 73% |
| CXCL13 | 96% | ErbB3-HER3 | 73% |
| CEA | 96% | TNF-R2 | 65% |
| FUR | 93% | TR-AP | 65% |
| Ep-CAM | 93% | KLK6 | 62% |
| AR | 93% | TRAIL-R2 | 62% |
| NEMO | 93% | FADD | 62% |
| KLK6 | 89% | LITAF | 62% |
| hK11 | 89% | NEMO | 62% |
| ErbB3-HER3 | 89% | eIF-4B | 62% |
| IL-6 | 82% | CA-125 | 58% |
| LAP-TGF-beta-1 | 82% | LAP-TGF-beta-1 | 50% |
| FasL | 82% | CSF-1 | 46% |
| CD69 | 82% | PARK7 | 46% |
| VIM | 82% | FUR | 46% |
| FR-alpha | 82% | CAIX | 42% |
| HGF | 79% | ErbB4-HER4 | 42% |
| ICOSLG | 79% | CD69 | 31% |
| CSF-1 | 71% | MIC-A | 31% |
| ErbB2-HER2 | 71% | AM | 27% |
| MIC-A | 71% | ErbB2-HER2 | 27% |
| VE-statin | 68% | Flt3L | 27% |
| CDH3 | 64% | CCL19 | 23% |
| Flt3L | 57% | PTPN22 | 23% |
| PECAM-1 | 57% | LYN | 23% |
| CCL19 | 54% | PECAM-1 | 23% |
| MYD88 | 54% | SCF | 15% |
| ILT-3 | 46% | HB-EGF | 15% |
| TNF-R2 | 46% | CXCL11 | 12% |
| PDGF-subunit-B | 39% | BAFF | 12% |
| TNF | 39% | TNFRSF4 | 12% |
| IL-7 | 36% | IL-12 | 8% |
| TNFSF14 | 36% | FasL | 8% |
| ErbB4-HER4 | 36% | MYD88 | 8% |
| ITGA1 | 36% | MIA | 8% |
| TRAIL-R2 | 32% | CDKN1A | 8% |
| CXCL11 | 32% | EGFR | 8% |
| SCF | 21% | ITGA1 | 8% |
| FS | 21% | FS | 8% |
| REG-4 | 18% | ILT-3 | 4% |
| HB-EGF | 14% | TIE2 | 4% |
| MMP-1 | 11% | PDGF-subunit-B | 4% |
| TIE2 | 7% | IL-2 | 4% |
| BAFF | 7% | IL-7 | 4% |
| MIA | 7% | IL-6RA | 4% |
| TNFRSF4 | 7% | MMP-1 | 4% |
| TR-AP | 7% | TNFSF14 | 4% |
| THPO | 7% | GH | 4% |
| NTRK3 | 7% | CDH3 | 4% |
| SELE | 4% | REG-4 | 4% |
| IL-12 | 4% | VEGF-D | 4% |
| PRL | 4% | IL-17RB | 4% |
| GH | 4% | CD40-L | 0% |
| CAIX | 4% | SELE | 0% |
| EGFR | 4% | EPO | 0% |
| CD40-L | 0% | VE-statin | 0% |
| EPO | 0% | PRL | 0% |
| IL-2 | 0% | TNF | 0% |
| IL-6RA | 0% | ICOSLG | 0% |
| VEGFR-2 | 0% | VEGFR-2 | 0% |
| IFN-gamma | 0% | IFN-gamma | 0% |
| VEGF-D | 0% | THPO | 0% |
| IL-17RB | 0% | NTRK3 | 0% |